Cancer Chemotherapy and Pharmacology

, Volume 30, Issue 4, pp 251–260 | Cite as

Do anticancer agents reach the tumor target in the human brain?

  • M. G. Donelli
  • M. Zucchetti
  • M. D'Incalci
Review Antitumoral Agents, Brain Pharmacokinetics, Central Nervous System, Human Tumors

Summary

The development of effective chemotherapy for tumors of the central nervous system (CNS) is complicated in that the blood-brain barrier (BBB) hampers the penetration of most drugs into the brain and cerebrospinal fluid (CSF). This review summarizes the main reports on the distribution to CNS tumors and peritumoral normal brain of antitumor agents such as epipodophyllotoxins,cis-diamminedichloroplatinum(II), some nitrosoureas, bleomycin, vinblastine, and other clinically used antitumor agents as well as that of some experimental compounds with specific physicochemical properties. Drug levels were measured at surgical resection or in autopsy samples taken from patients who presented with different primary brain tumors or with brain metastases from extracerebral tumors. The observations made in each study were summarized in some detail, and the main points were then evaluated comparatively so as to highlight common aspects in the pharmacokinetic patterns of antitumor agents in human CNS tumors. Independently of their physicochemical properties, most antitumor agents appear to accumulate to a greater extent and to persist longer in intracerebral tumors than in the normal peritumoral brain. From in vitro cytotoxicity assays, it appears that epipodophyllotoxins, platinum compounds, bleomycin, and nitrosoureas reach potentially active therapeutic concentrations at the tumor target. However, all drugs have difficulty in reaching brain tissue adjacent to the tumor, as the intact BBB hampers their penetration. Plasma and CSF drug concentrations usually give little useful indication of the absolute quantity of drugs in brain tumors. To obtain a clear understanding of the CNS distribution of antitumor agents, one must determine whether the compound being measured is actually responsible for the observed activity and must consider the role of metabolites in the effect of the parent drug.

Abbreviations

AZQ

aziridinylbenzoquinone

BBB

blood-brain barrier

CNS

central nervous system

CSF

cerebrospinal fluid

BCNU

carmustine

BLEO

bleomycin

CDDP

cisplatin

DAU

3-deazauridine

DBD

dibromodulcitol

DTIC

dimethyl triazene imidazole carboxamide

MGBG

methylglyoxal bis(guanylhydrazone)

MITXR

mitoxantrone

PALA

N-phosphonacetyl-l-aspartate

PMM

pentamethylmelamine

TCNU

tauromustine

VLB

vinblastine

VM-26

teniposide

VP-16

etoposide

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Balis FM, Poplack DG (1989) Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 11: 74Google Scholar
  2. 2.
    Balis FM, Savitch JL, Bleyer WA, Reaman GH, Poplack DG (1985) Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 3: 485Google Scholar
  3. 3.
    Blasberg RG, Groothuis DR (1986) Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol 13: 70Google Scholar
  4. 4.
    Bleyer XWA, Poplack DG (1979) Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 6: 207Google Scholar
  5. 5.
    Bogdahn U (1983) Chemosensitivity of malignant human brain tumors. Preliminary results. J Neurooncol 1: 149Google Scholar
  6. 6.
    Bonati M, Kanto J, Tognoni G (1982) Clinical pharmacokinetics of cerebrospinal fluid. Clin Pharmacokinet 7: 312Google Scholar
  7. 7.
    Bonnem EM, Litterst CL, Smith FP (1982) Platinum concentrations in human glioblastoma multiforme following the use of cisplatin. Cancer Treat Rep 66: 1661Google Scholar
  8. 8.
    Borsi JD, Moe PJ (1987) Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 60: 3020Google Scholar
  9. 9.
    Brooks DJ, Beaney RP, Thomas DGT (1986) The role of positron emission tomography in the study of cerebral tumors. Semin Oncol 13: 83Google Scholar
  10. 10.
    Chamberlain MC, Prados MD, Silver P, Levin VA (1988) A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors. J Neurooncol 6: 319Google Scholar
  11. 11.
    Chiras J, Dormont D, Fauchon F, Debussche C, Bories J (1988) Intra-arterial chemotherapy of malignant gliomas. J Neuroradiol 15: 31Google Scholar
  12. 12.
    Choucair AK (1990) Proposals for evaluation of toxic effects associated with treatment of gliomas: a call for action. J Natl Cancer Inst 82: 531Google Scholar
  13. 13.
    Collins JM, Dedrick RL (1983) Distributed model for drug delivery to CSF and brain tissue. Am J Physiol 245: R303Google Scholar
  14. 14.
    Collins JM, Grieshaber CK, Chabner BA(1990) Pharmacologically guided phase I clinical trials upon preclinical drug development. J Natl Cancer Inst 82: 1321Google Scholar
  15. 15.
    Csetényi J, Afra D, Kerpel-Fronius S, Horvath IP, Institoris L, Eckhardt S (1983) The distribution of [3H]-dibromodulcitol in the central nervous system of patients with brain tumour. Eur J Cancer Clin Oncol 19: 1389Google Scholar
  16. 16.
    Diksic M, Sako K, Feindel W, Kato A, Yamaoto YL, Farrokhzad S, Thompson C (1984) Pharmacokinetics of positron-labeled 1,3-bis(2-cholorethyl)nitrosourea in human brain tumors using positron emission tomography. Cancer Res 44: 3120Google Scholar
  17. 17.
    D'Incalci M, Sessa C, Beggiolin G, Mangioni C (1981) Cerebrospinal fluid levels of hexamethylmelamine andN-demethylated metabolites. Cancer Treat Rep 65: 350Google Scholar
  18. 18.
    D'Incalci M, Farina P, Sessa C, Mangioni C, Conter V, Masera G, Rocchetti M, Brambilla Pisoni M, Piazza E, Beer M, Cavalli F (1982) Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 7: 141Google Scholar
  19. 19.
    Dow LW, Sinkule JA, Look AT, Horvath A, Evans WE (1983) Comparative cytotoxic and cytokinetic effects of the epipodophyl-lotoxins 4′-demethylepipodophylotoxin-9-(4,6-O-2-ethylidene-β-d-glucopyranoside) and 4′-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-β-d-glucopyranoside) and their metabolites on human leukemic lymphoblasts. Cancer Res 43: 5699Google Scholar
  20. 20.
    Duffner PK, Cohen ME, Parker MS (1988) Prospective intellectual testing in children with brain tumors. Ann Neurol23: 575Google Scholar
  21. 21.
    Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G (1982) Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol 7: 147Google Scholar
  22. 22.
    Evans WE, Crom WR, Stewart CE, Bowman WP, Chen C-H, Abromowitch M, Simone JV (1984) Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet I: 359Google Scholar
  23. 23.
    Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, George SL, Pui C-H (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 314: 471Google Scholar
  24. 24.
    Front D, Israel O, Kohn S, Nir I (1984) The blood-tissue barrier of human brain tumors: correlation of scintigraphic and ultrastructural findings: concise communication. J Nucl Med 25: 461Google Scholar
  25. 25.
    Front D, Even-Sapir E, Iosilevsky G, Israel O, Frenkel A, Kolodny GM, Feinsod M (1987) Monitoring of [57Co]-bleomycin delivery to brain metastases and their tumors of origin. J Neurosurg 67: 506Google Scholar
  26. 26.
    Front D, Israel O, Iosilevsky G, Even-Sapir E, Frenkel A, Kolodny GM, Feinsod M (1988) SPECT quantitation of cobalt-57 bleomycin delivery to human brain tumors. J Nucl Med 29: 187Google Scholar
  27. 27.
    Geran RI, Congleton GF, Dudeck LE, Abbott BJ, Gargus JL (1974) A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs. Cancer Chemother Rep 4: 53Google Scholar
  28. 28.
    Green RM, Stewart DJ, Hogenholtz H, Richard MT, Thibault M, Montpetit V (1988) Human central nervous system and plasma pharmacology of mitoxantrone. J Neurooncol 6: 75Google Scholar
  29. 29.
    Greig NH (1987) Optimizing drug delivery to brain tumors. Cancer Treat Rev 14: 1Google Scholar
  30. 30.
    Greig NH, Sweeny D (1987) Brain tumors and the blood brain barrier. In: Neuwelt E (ed) The clinical impact of the blood-brain barrier and its manipulation. Plenum, New York, p 93Google Scholar
  31. 31.
    Hill BT, Whelan RDH, Rupniak HT, Dennis LY, Rosholt MA (1981) A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Pharmacol 7: 21Google Scholar
  32. 32.
    Instittoris L, Dzurillay E (1973) Comparative studies on the in vivo distribution pattern of dibromodulcitol and diepoxydulcitol. Z Krebsforsch 79: 49Google Scholar
  33. 33.
    Iwata K, Yung WKA, Fields WS (1988) In vitro effects of ACNU, BCNU, CDDP, and bleomycin on human glioma cells. Neurol Med Chir (Tokyo) 28: 965Google Scholar
  34. 34.
    Kaplan RS, Wiernik PH (1982) Neurotoxicity of antineoplastic drugs. Semin Oncol 9: 103Google Scholar
  35. 35.
    Kimmel DW, Shapiro JR, Shapiro WR (1987) In vitro drug sensitivity testing in human gliomas. J Neurosurg 66: 161Google Scholar
  36. 36.
    Lennard L, Keen D, Lylleyman JS (1986) Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 40:287Google Scholar
  37. 37.
    Levin VA (1975) A pharmacologic basis for brain tumor chemotherapy. Semin Oncol 2: 57Google Scholar
  38. 38.
    Levin VA, Hoffman W, Weinkam RJ (1978) Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. Cancer Treat Rep 62: 1305Google Scholar
  39. 39.
    Lippens RJ, Winograd B (1988) Methotrexate concentration levels in the cerebrospinal fluid high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol 5: 115Google Scholar
  40. 40.
    Mahaley MS, Whaley RA, Blue M, Bertsch L (1986) Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas. J Neurooncol 3: 297Google Scholar
  41. 41.
    McSheehy PMJ, Griffiths JR (1989)19F MRS studies of fluoropyrimidine chemotherapy. A review. Nucl Magn Reson Biomed 2: 133Google Scholar
  42. 42.
    Miller KT, Wilkinson DS (1989) Pharmacokinetics of methotrexate in the cerebrospinal fluid after intracerebroventricular administration in patients with meningeal carcinomatosis and altered cerebrospinal fluid flow dynamics. Ther Drug Monit 11: 231Google Scholar
  43. 43.
    Neuwelt EA (1985) Therapeutic potential for blood-brain barrier modification in malignant brain tumor. Prog Exp Tumor Res 28: 51Google Scholar
  44. 44.
    Neuwelt E, Hill S (1986) Chemotherapy administered in conjuction with osmotic blood-brain barrier modification in patients with brain metastases. J Neurooncol 4: 195Google Scholar
  45. 45.
    Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH, Gibson AC (1992) Phase I trial of temozolomide. Abstract 50, Meeting of the EORTC Pharmacology and Molecular Mechanism Group, Bologna, January 9–11Google Scholar
  46. 46.
    O'Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S (1984) Teniposide. A review of 12 years of experience. Cancer Treat Rep 68: 1455Google Scholar
  47. 47.
    O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Drug therapy. Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Med 312: 692Google Scholar
  48. 48.
    Ommaya AK (1984) Implantable devices for chronic access and drug delivery to the central nervous system. Cancer Drug Deliv 1: 16Google Scholar
  49. 49.
    Packer RJ, Sutton LN, Atkins TE, Radcliffe J, Bunin GR, D'Angio G, Siegel KR, Schut L (1989) A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg 70: 707Google Scholar
  50. 50.
    Poplack DG, Riccardi R (1987) Pharmacologic approaches to the treatment of central nervous system malignancy. In: Poplack DG, Massimo L, Cornaglia-Ferraris P (eds) The role of pharmacology in pediatric oncology. Martinus Nijhoff, Boston, p 137Google Scholar
  51. 51.
    Poplack DG, Reaman GH, Bleyer WA, Miser J, Feusner J, Wesley R, Hammond D (1984) Central nervous system (CNS) preventive therapy with high-dose methotrexate (HDMTX) in acute lymphoblastic leukemia (ALL): a preliminary report. Proc Am Soc Clin Oncol 3: 204Google Scholar
  52. 52.
    Qin DX, Zheng R, Tang J, Li JX, Hu YH (1990) Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys 19: 1507Google Scholar
  53. 53.
    Radice PA, Bunn PA Jr, Ihde DC (1979) Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep 63: 1231Google Scholar
  54. 54.
    Rapoport SI, Fredericks WR, Ohno K, Pettigrew KD (1980) Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 238: R 421Google Scholar
  55. 55.
    Reid JM, Pendergrass TW, Krailo MD,Hammond GD, Ames MM (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res 50: 6525Google Scholar
  56. 56.
    Roed H, Vindelov LL, Christensen IJ, Spang-Thomsen M, Hansen HH (1987) The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. Cancer Chemother Pharmacol 19: 16Google Scholar
  57. 57.
    Roper PR, Drewinko B (1976) Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 36: 2182Google Scholar
  58. 58.
    Rosenblum MG, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL (1981) Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans.Cancer Res 41: 459Google Scholar
  59. 59.
    Rosenblum ML, Wheeler KT, Wilson CB, Barker M, Knebel KD (1975) In vitro evaluation of in vivo brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 35: 1387Google Scholar
  60. 60.
    Rosenblum ML, Dougherty DA, Deen DF, Hoshino T, Wilson CB (1980) Analysis of clonogenic human brain tumour cells: preliminary results of tumour sensitivity testing with BCNU. Br J Cancer 41 [Suppl IV]: 181Google Scholar
  61. 61.
    Savaraj N, Lu K, Feun LG, Leavens ME, Stewart D, Burgess MA, Benjamin RS, Loo TL (1983) Intracerebral penetration and tissue distribution of 2,5-diaziridinyl-3,6-bis(carboethoxyamino)1,4-benzoquinone (AZQ, NSC-182 986). J Neurooncol 1: 15Google Scholar
  62. 62.
    Sessa C, Zucchetti M, Davoli E, Califano R, Cavalli F, Frustaci S, Gumbrell L, Sulkes A, Winograd B, D'Incalci M (1991) Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst 81: 1160Google Scholar
  63. 63.
    Shapiro WR (1986) Therapy of adult malignant brain tumors: what have the clinical trials taught us? Semin Oncol 13: 38Google Scholar
  64. 64.
    Siegers HP (1990) Chemotherapy for brain metastases: recent developments and clinical considerations. Cancer Treat Rev 17: 63Google Scholar
  65. 65.
    Stewart DJ (1986) Phase II study of novantrone (mitoxantrone hydrochloride) in adults with grade III–IV astrocytomas. In: Walker MD, Thomas DGT (eds) Biology of brain tumor. Martinus Nijhoff, Boston, p 411Google Scholar
  66. 66.
    Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KB, Burgess MA, Loo TL (1979) Penetration of 3-deazauridine into human brain,intracerebral tumor, and cerebrospinal fluid. Cancer Res 39: 4119Google Scholar
  67. 67.
    Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo TL (1980) Penetration ofN-(phosphonacetyl)-l-aspartate into human central nervous system and intracerebral tumor. Cancer Res 40: 3163Google Scholar
  68. 68.
    Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS (1982) Human central nervous system distribution ofcis-diamminedichloroplatinum and its use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474Google Scholar
  69. 69.
    Stewart DJ, Benvenuto JA, Leavens M, Smith RG, Cabanillas F, Benjamin RS, Loo TL (1983) Human central nervous system pharmacology of pentamethylmelamine and its metabolites. J Neurooncol 1: 357Google Scholar
  70. 70.
    Stewart DJ, Lu K, Benjamin RS, Leavens ME, Luna M, Yap H-Y, Loo TL (1983) Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neurooncol 1: 139Google Scholar
  71. 71.
    Stewart DJ, Richard MT, Hugenholtz H, Dennery JM, Belanger R, Gerin-Lajoie J, Montpetit V, Nundy D, Prior J, Hopkins HS (1984) Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neurooncol 2: 133Google Scholar
  72. 72.
    Stewart DJ, Richard MT, Hugenholtz H, Dennery J, Nundy D, Prior J, Montpetit V, Hopkins HS (1984) Penetration of teniposide (VM-26) into human intracerebral tumors. J Neurooncol 2: 315Google Scholar
  73. 73.
    Stewart DJ, Mikhael NZ, Nair RC, Kacew S, Montpetit V, Nanji A, Maroun JA, Howard K (1988) Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol 11: 152Google Scholar
  74. 74.
    Tirelli D, D'Incalci M, Canetta R, Tumolo S, Franchin G, Veronesi A, Galligioni E, Trovò MG, Rossi C, Grigoletto E (1984) Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol 2: 432Google Scholar
  75. 75.
    Von Hoff DD, Coltman CA Jr, Forseth B (1981) Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41: 1853Google Scholar
  76. 76.
    Walker MD, Weiss H (1975) Chemotherapy in the treatment of malignant brain tumors. Adv Neurol 13: 149Google Scholar
  77. 77.
    Watts C (1987) Blood-brain barrier and drug delivery in central nervous system tumors. Ann Neurol 21: 614Google Scholar
  78. 78.
    Whittle IR, MacPherson JS, Miller JD, Smyth JF (1990) The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications. J Neurosurg 72: 721Google Scholar
  79. 79.
    Workman P (1985) The pharmacology of brain tumor chemotherapy. In: Bleehen NM (ed) Tumors of the brain. Springer, Berlin Heidelberg New York, p 183Google Scholar
  80. 80.
    Yamada K, Takahama H, Nakai O, Takanashi T, Hosoya T (1989) Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption. Gan To Nakagu Ryoho 16: 2692Google Scholar
  81. 81.
    Yung W-KA, Shapiro JR, Shapiro WR (1982) Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42: 992Google Scholar
  82. 82.
    Yung W-KA, Harris MI, Bruner JM, Feun LG (1989) Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neurooncol 7: 237Google Scholar
  83. 83.
    Zucchetti M, Rossi C, Knerich R,Donelli MG, Butti G, Silvani V, Gaetani P, D'Incalci M (1991) Concentrations of VP16 and VM26 in human brain tumors. Ann Oncol 2: 63Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • M. G. Donelli
    • 1
    • 2
  • M. Zucchetti
    • 1
  • M. D'Incalci
    • 1
  1. 1.Instituto di Ricerche Farmacologische Mario NegriMILANOItaly
  2. 2.Dipartimento di Biologia e Genetica per le Scienze MedicheMilanoItaly

Personalised recommendations